- e-mail us
- We are Open
Nuclear Medicine & Radiopharmaceuticals
We are looking for you to help us make sure our products are efficiently distributed countrywide
Interested in
Partnership
Email or
Call Us
Nuclear Medicine Products & Radiopharmaceuticals
Prospectus Therapeutics is at the forefront of nuclear medicine, offering a comprehensive range of products and radiopharmaceuticals designed for both diagnostic and therapeutic applications in modern healthcare.
Leading the Way in Nuclear Medicine
At Prospectus Therapeutics, our focus is on providing cutting-edge solutions in nuclear medicine. Our products are designed to enhance diagnostic accuracy and therapeutic efficacy, ensuring better patient outcomes. We are committed to innovation, quality, and safety in all our nuclear medicine products and radiopharmaceuticals.
| SEGMENT | CLASSIFICATION | PRODUCT | SPECIFICATION |
|---|---|---|---|
| PET | CASSETTES AND REAGENTS | [18F]FDG | Reagent Kits and Cassettes for the automated synthesis of 2-[¹⁸F]Fluoro-2-deoxy-D-glucose. The FASTlab™ FDG Cassette is a single use, disposable fluid path containing reagents and auxiliary materials required for the synthesis of [18F]FDG using the FASTlab™ Synthesiser. The Cassette Pack contains the following reagent components: 4mlAcetonitrile, 4ml 2M Sodium Hydroxide, 4ml 22.5% Phosphoric Acid in water. Mannose Triflate 2% in Acetonitrile, Elution vial 0.825ml containing 50mg Kryptofix®222 (4,7,13,16,21,24-Hexaoxa-1,10 diazabicyclo[8.8.8]hexacosane), 10mg Potassium Carbonate in 80% Acetonitrile 20% water |
| PET | CASSETTES AND REAGENTS | [18F]PSMA-1007 | Reagent Kits and Cassettes for the automated synthesis of [¹⁸F]PSMA-1007 |
| PET | MOLECULES AND ACCESSORIES | FDG | Reference standard for [¹⁸F]FDG synthesis (2-[¹⁸F]fluoro-2-deoxy-D-glucose) Other names: 2-Deoxy-2-fluoro-D-glucose 2-Deoxy-fluoro-glucose Fludeoxyglucose D-Glucopyranose, 2-deoxy-2-fluoro CHARACTERISTICS: Molar mass 182.15 CAS RN [86783-82-6] (pyranoside); [29702-43-0] (aldehyde) Purity ≥ 95 % Colorless to off-white solid soluble in methanol, dimethyl sulfoxide, water |
| PET | MOLECULES AND ACCESSORIES | FDM | Reference standard for byproduct of [¹⁸F]FDG synthesis (2-[¹⁸F]fluoro-2-deoxy-D-glucose) Other names: 2-Fluoro-2-deoxy-D-mannopyranose 2-Deoxy-2-fluoro-D-mannopyranose D-Mannopyranose, 2-deoxy-2-fluoro CHARACTERISTICS: Molar mass 182.15 CAS RN [31077-88-0] Purity ≥ 95 % Colorless to slightly colored semisolid/solid |
| PET | MOLECULES AND ACCESSORIES | TATM | Mannose triflate Reference standard Other names: Beta-D-Mannopyranose 1,3,4,6-tetra-O-acetate 2-O-trifluoromethanesulfonate; 1,3,4,6-Tetra-O-acetyl-2-O-trifluoromethanesulfonyl-beta-D-mannopyranose |
| PET | MOLECULES AND ACCESSORIES | TBA | Tetrabutylammonium Hydrogen Carbonate (0.075 M) Other names: Tetrabutylammonium hydrogen carbonate solution; – – Tetrabutylammonium bicarbonate Uses: Reagent for radiolabelling synthesis/labelling of PET molecules using the GE Synthesizer modules CHARACTERISTICS: Clear and colourless aqueous solution, stabilized with ethanol Usually used to elute [¹⁸F]fluoride ions from QMA cartridge to reaction vessel |
| PET | MOLECULES AND ACCESSORIES | KRYPTOFIX 222 | Phase transfer catalysts for the synthesis of radiopharmaceutical preparations Other names: 2,2,2-Cryptand 2,2,2-Cryptate Cryptand 2.2.2 Cryptate 222 Cryptating agent 222 Cryptofix 222 Kryptand 222 Kryptofix 222 4,7,13,16,21,24-Hexaoxa-1,10 diazabicyclo[8.8.8]hexacosane |
| SPECT | GENERATORS | Molybdenum-99/Technetium-99m (99Mo/99mTc) Generator | 99Mo/99mTc radionuclide generators are used for the labeling of radiopharmaceutical kits or directly by producing radioactive materials extracted from them. They contain the fission product Molybdenum-99 (99Mo) adsorbed on aluminum oxide (Al2O3) in a glass column. Technetium-99m (99mTc), formed by the decay of 99Mo, is a radioactive isotope with a half-life of 6.01 hours. Technetium-99m is extracted from the generator in the form of sodium pertechnetate (Na99mTcO4) solution through an elution process, and it is used to label SPECT diagnostic radiopharmaceutical kits to diagnose and identify types of cancers and diseases. The half-life of Tc-99m of 6.01 hours, which is an appropriate time to acquire medical information making it not such long for the patient to receive unnecessary radiation. Also, as gamma rays emitted from Tc-99m have enough energy (140Kev) to penetrate the tissue, it is appropriate to be used for diagnostic purposes. The useful life of the generator is about three half-lives of the mother radioisotope, molybdenum-99, which is about one week. Pharmaceutical form: Radionuclide generator. Sodium pertechnetate (99mTc) solution: clear and colourless. Active ingredients: Parent nuclide: (99Mo) Sodium Molibdate (Na99MoO4) 5-50 GBq/generator (99Mo radioactivity on calibration day) Daughter nuclide: (99mTc) Sodium Pertechnetate (Na99mTcO4) (eluted from 99Mo99mTc generator system) |
| SPECT | RADIOPHARMACEUTICAL KITS FOR DIAGNOSTIC | MIBI | Used for myocardial, parathyroid, and breast imaging after labeling with 99mTc CONTENT: 1 vial contains 1.00 mg tetrakis (2-methoxyisobutylisonitrile) copper (I) tetrafluoroborate (MIBI) Not directly administered to the patient. Administered as IV radiopharmaceutical obtained after labeling with (99mTc) Sodium Pertechnetate solution. |
| SPECT | RADIOPHARMACEUTICAL KITS FOR DIAGNOSTIC | MDP | Used for imaging of the bones by labeling with 99mTc. CONTENT: 1 vial contain 10 mg methylenediphosphonic acid (MDP) Not directly administered to the patient. Administered as IV radiopharmaceutical obtained after labeling with (99mTc) Sodium Pertechnetate solution. |
| SPECT | RADIOPHARMACEUTICAL KITS FOR DIAGNOSTIC | MAA | Used for imaging of the cardiovascular system and lungs by labeling with 99mTc CONTENT: 1 vial contains 3.0 mg human serum albumin macroaggregates Not directly administered to the patient. Administered as a radiopharmaceutical through intravenous intrathecal, inhalation, or oral routes after labeling with (99mTc) Sodium Pertechnetate solution depending on the examination. |
| SPECT | RADIOPHARMACEUTICAL KITS FOR DIAGNOSTIC | DTPA | Used for imaging the kidneys and brain by labeling with 99mTc. CONTENT: 1 vial contain 35 mg diethylenetriaminepentaacetic calcium trisodium hydrate (DTPA-Ca) Not directly administered to the patient. Administered as a radiopharmaceutical through intravenous intrathecal, inhalation, or oral routes after labeling with (99mTc) Sodium Pertechnetate solution depending on the examination. |
| SPECT | RADIOPHARMACEUTICAL KITS FOR DIAGNOSTIC | DMSA | Used for imaging of the kidneys (renal scintigraphy) by labeling with 99mTc CONTENT: 1 vial contains 1.0 mg dimercaptosuccinic acid (DMSA) Not directly administered to the patient. Administered as IV radiopharmaceutical obtained after labeling with (99mTc) Sodium Pertechnetate solution. |
| SPECT | RADIOPHARMACEUTICAL KITS FOR DIAGNOSTIC | MAG3 | Used for imaging of the kidneys (renal scintigraphy) by labeling with 99mTc CONTENT: 1 vial contains 1 mg mercaptoacetyltriglycine (mertiatide) (MAG3) Not directly administered to the patient. Administered as IV radiopharmaceutical obtained after labeling with (99mTc) Sodium Pertechnetate solution. |
| SPECT | RADIOPHARMACEUTICAL KITS FOR DIAGNOSTIC | SULPHUR COLLOID | Used for imaging of liver, spleen and renal systems CONTENT: 1 vial contains sodium thiosulfate, gelatin and sodium edetate Not directly administered to the patient. Administered as IV radiopharmaceutical obtained after labeling with (99mTc) Sodium Pertechnetate solution. |
| RADIOPHAMACEUTICALS | THERAPEUTIC | Iodine 131 (I-131) Oral solution | Used in thyroid metastases, toxic nodular goiter and hyperthyroidism for treatment purposes. Used in the diagnosis of thyroid function disorders (hyperthyroidism and hypothyroidism), evaluation of thyroid tissue location and analysis of thyroid lesions CONTENT: Sodium iodide Na131I, solution for injection |
| RADIOPHAMACEUTICALS | DIAGNOSTIC | Iodine 131 (I-131) Capsules | Used in thyroid scanning for diagnostic purposes. Used in thyroid cancer, toxic nodular goiter, toxic diffuse goiter diseases, and hyperthyroidism for treatment purposes. CONTENT: Hard gelatin oral capsule containing sodium iodide (Na131I). |
| RADIOPROTECTION | LEAD | Lead Shields for Vials | Offers operators radiation protection and ergonomic solution for storing radioactive liquid preparations in nuclear medicine. It allows easy syringe sampling of SPECT radiopharmaceuticals while limiting user exposure. |
| RADIOPROTECTION | LEAD | Lead Shields for Syringes | Used to reduce radiation to the user’s hands and fingers during manual preparation, transfer and injection of radiopharmaceuticals. Shielding is provided by lead glass Available in a wide range of sizes and shielding thickness to accommodate user’s requirements |
| RADIOPROTECTION | TUNGSTEN | Tungsten Shields for Syringes | Used to reduce radiation to the user’s hands and fingers during manual preparation, transfer and injection of radiopharmaceuticals. Shielding is provided by tungsten. Available in a wide range of sizes and shielding thickness to accommodate user’s requirements |
| RADIOPROTECTION | LEAD | Lead Shielded Pots for Elution | Used to perform 99Mo/99mTc radiopharmaceutical generator elutions and to collect the injectable sodium pertechnetate (99mTc) stock solution for the radiolabeling of radiopharmaceutical kits used to perform scintigraphic examinations in conventional nuclear medicine or SPECT |
| RADIOPROTECTION | LEAD | Lead Shielded Waste Bin | Used to facilitate the storage, containment and decay of contaminated and radioactive potentially infectious medical waste (PIMW) of SPECT and PET activities providing the appropriate protection for the time needed for radioactive decay before waste disposal. |
| RADIOPROTECTION | LEAD | Shielded Transport and Storage Containers | Used during transfer and storage of radioactive sources to protect operators and the environment from contamination and exposure to alpha, beta, gamma and neutron radiation. |
| RADIOPROTECTION | LEAD | Shielded Microbiological Safety Cabinet for Preparation of Radiopharmaceuticals | Suitable for performing radioisotope cell labelling, 99Mo/99mTc generator elutions, kit reconstitution and radiolabeling and fractionating of patient doses of radiopharmaceuticals used in nuclear medicine under laminar flow hood protection also allows for them in an ISO 5 (class A) working environment |
| MEDICAL IMAGING SOURCES | SPECT SOURCES | Cobalt 57 (Co-57) Flood Sources | Used to provide a uniform field of radiation for evaluation of Nuclear Medicine gamma camera performance, allowing detection and correction of any camera malfunction prior to diagnostic use. The flood sources are available in a variety of circular and rectangular dimensions, with activities to meet the standards established by the manufacturers of the gamma cameras. Useful life is approximately 2 years Packaging: Type A packaging |
| MEDICAL IMAGING SOURCES | PET SOURCES | Germanium 68 (Ge-68) Phantom | The PET Annulus DQA (Daily Quality Assurance) imaging phantom for the PET/CT system is a uniform solid suspension of Ge-68 encased and sealed in an annular, black plastic shell. Recommended for accurate calibration of PET detectors and for quality control Useful life is approximately 1-2 years. Packaging: Type A packaging |
About Prospectus
Prospectus Therapeutics is a Kenyan healthcare company specializing in the supply of pharmaceuticals, non-pharmaceuticals, nuclear medicine products, radiopharmaceuticals, and medical technology solutions. With over 30 years of experience, they are dedicated to delivering impactful therapies and advanced medical solutions across Kenya. Business Segments: Pharmaceuticals: Offering a wide range of cost-effective, high-quality medications focusing on efficacy and patient safety. Non-Pharmaceuticals: Providing essential healthcare products, including medical consumables, surgical supplies, public health commodities, and waste management solutions. Nuclear Medicine: Supplying innovative nuclear medicine products and radiopharmaceuticals for diagnostic and therapeutic uses, adhering to strict safety standards. Medical Technology Solutions: Equipping healthcare facilities with cutting-edge medical technology, ensuring providers are prepared to address emerging and prevalent medical needs. Key Areas of Interest: Pharmaceuticals (Human & Veterinary) Medical Equipment & Accessories Hospital Furniture & Accessories Surgical Instruments & Equipment Laboratory Equipment & Consumables Public Health Solutions Hospital Waste Management Agrovet Inputs & Equipment Animal Vaccines Mission: Prospectus Therapeutics is committed to upholding social responsibility by equitably delivering quality medical care and advanced pharmaceutical solutions across Kenya. For more information or to explore partnership opportunities, visit their website at https://prospectus.co.ke/.